Jean-Philippe Combal | Co-Founder & CEO
Vivet Therapeutics

More than 30 years of experience in the pharma & biotech industries. Skilled senior executive with a broad range of experience leading global development, corporate strategy and a successful track record of innovation and development in the area of Orphan Drugs. Co-founder & CEO at Vivet Therapeutics, who made an option deal with Pfizer in 2019 and licensing deal with Mirum, with focus on the treatment of AAV Neutralising Antibody positive population. Chief Operating Officer of GenSight Biologics (2014-2017), he was instrumental for investment rounds of more than 150M$, including a successful EuroNext IPO and piloted the advancement of two major gene therapy programs from non-clinical to phase 3 pivotal trials. Previously, Strategic Therapeutic Area Leader at Galderma International and prior to that held the role of Vice President of Drug Development followed by Strategic Marketing at Sanofi (Ophthalmic Division after Fovea Pharmaceuticals acquisition; 2006-2011). Chairman, Board of Directors of SpliceBio SL, Gene therapy company ( Barcelona) ; Advisor & Non-executive Director at Ikarovec Ltd (London) an ophthalmologic gene therapy company in dry-AMD.